• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,202.87
  • 0.66 %
  • $53.60
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Cerevel Therapeutics Holdings, Inc. (CERE) Stock Price, News & Analysis

Cerevel Therapeutics Holdings, Inc. (CERE) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$44.96
Day's range
$44.99
50-day range
$38.5
Day's range
$44.99
  • Country: US
  • ISIN: US15678U1280
52 wk range
$19.59
Day's range
$44.99
  • CEO: Mr. Ronald C. Renaud Jr., M.B.A.
  • Website: Visit Site
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 6.28
  • Piotroski Score 3.00
  • Grade Neutral
  • Symbol (CERE)
  • Company Cerevel Therapeutics Holdings, Inc.
  • Price $44.96
  • Changes Percentage (0.74%)
  • Change $0.33
  • Day Low $44.96
  • Day High $44.99
  • Year High $44.99

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 08/07/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $33.50
  • High Stock Price Target $40.00
  • Low Stock Price Target $27.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.73
  • Trailing P/E Ratio -14.66
  • Forward P/E Ratio -14.66
  • P/E Growth -14.66
  • Net Income $-432,842,000

Income Statement

Quarterly

Annual

Latest News of CERE

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Cerevel Therapeutics Holdings, Inc. Frequently Asked Questions

  • What is the Cerevel Therapeutics Holdings, Inc. stock price today?

    Today's price of Cerevel Therapeutics Holdings, Inc. is $44.96 — it has increased by +0.74% in the past 24 hours. Watch Cerevel Therapeutics Holdings, Inc. stock price performance more closely on the chart.

  • Does Cerevel Therapeutics Holdings, Inc. release reports?

    Yes, you can track Cerevel Therapeutics Holdings, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Cerevel Therapeutics Holdings, Inc. stock forecast?

    Watch the Cerevel Therapeutics Holdings, Inc. chart and read a more detailed Cerevel Therapeutics Holdings, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Cerevel Therapeutics Holdings, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Cerevel Therapeutics Holdings, Inc. stock ticker.

  • How to buy Cerevel Therapeutics Holdings, Inc. stocks?

    Like other stocks, CERE shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Cerevel Therapeutics Holdings, Inc.'s EBITDA?

    Cerevel Therapeutics Holdings, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Cerevel Therapeutics Holdings, Inc.’s financial statements.

  • What is the Cerevel Therapeutics Holdings, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Cerevel Therapeutics Holdings, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Cerevel Therapeutics Holdings, Inc.'s financials relevant news, and technical analysis. Cerevel Therapeutics Holdings, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Cerevel Therapeutics Holdings, Inc. stock currently indicates a “sell” signal. For more insights, review Cerevel Therapeutics Holdings, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.